Aaron Seth Kesselheim
Aaron Seth Kesselheim publishes mostly in Economics and Econometrics, Pharmacology and Pediatrics, Perinatology and Child Health, on topics such as Pharmaceutical Economics and Policy, Health Systems, Economic Evaluations, Quality of Life and Pharmaceutical industry and healthcare.
- World rank
- #47,545 of 7,710,434 ranked researchers
- Rank in United States
- #18,341 of 1,627,098
- Works
- 1,011
- Citations
- 25k
- Citations per work
- 25.1
What does Aaron Seth Kesselheim research?
Aaron Seth Kesselheim's work is mostly in Economics, Econometrics and Finance (39%), Medicine (16%), Pharmacology, Toxicology and Pharmaceutics (8%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Social Sciences39038.6%
- Everything else35134.7%
- Health Sciences16015.8%
- Medicine16015.8%
- Life Sciences11010.9%
- 1Economics and Econometrics39% of their works
- 2Pharmacology8% of their works
- 3Pediatrics, Perinatology and Child Health6% of their works
- 4Physiology5% of their works
- 5Public Health, Environmental and Occupational Health5% of their works
- 6Immunology3% of their works
Research topics
- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical industry and healthcare
- Pharmaceutical studies and practices
- Biomedical Ethics and Regulation
- Biosimilars and Bioanalytical Methods
- Economic and Financial Impacts of Cancer
- Medication Adherence and Compliance
Which keywords describe Aaron Seth Kesselheim's research?
The keywords of their largest research topics: Pharmaceutical Industry, Drug Development Costs, Generic Drugs, Clinical Trials, Cost-effectiveness Analysis, Quality of Life, Medication Adherence and Conflict of Interest.
- Patient Compliance
- Cost of Care
- Biosimilars
- Regulatory Challenges
- Off-Label Drug Use
- Conflict of Interest
- Quality of Life
- Clinical Trials
- Drug Development Costs
- Pharmaceutical Industry
- Generic Drugs
- Cost-effectiveness Analysis
- Medication Adherence
- Research Outcome
- Pediatric Pharmacokinetics
- Stem Cell Regulation
- Immunogenicity
- Financial Toxicity
- Treatment Adherence
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 19 words, with their numbers
- Pharmaceutical Industry7652 topics
- Drug Development Costs5421 topic
- Generic Drugs5421 topic
- Clinical Trials5063 topics
- Cost-effectiveness Analysis4171 topic
- Quality of Life4171 topic
- Medication Adherence2392 topics
- Conflict of Interest2231 topic
- Research Outcome2231 topic
- Off-Label Drug Use1651 topic
- Pediatric Pharmacokinetics1651 topic
- Regulatory Challenges1181 topic
- Stem Cell Regulation1181 topic
- Biosimilars801 topic
- Immunogenicity801 topic
- Cost of Care781 topic
- Financial Toxicity781 topic
- Patient Compliance741 topic
- Treatment Adherence741 topic
Where does Aaron Seth Kesselheim work?
Aaron Seth Kesselheim's main affiliation in the publication record is Brigham and Women's Hospital, United States.
How many publications and citations does Aaron Seth Kesselheim have?
OpenAlex counts 1,011 works and 25,378 citations for Aaron Seth Kesselheim, an h-index of 77, ranking #47,545 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Aaron Seth Kesselheim. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.